Anthera Pharmaceuticals Inc (NASDAQ:ANTH) Investor Investigation In Connection With Executive Compensation Announced

If you are a current long-term stockholder of shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH), you have certain options and you should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this investigation, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Anthera Pharmaceuticals
Affected Securities: 
NASDAQ: ANTH

Jan. 25, 2013 (Shareholders Foundation) -- An investigation on behalf of current long term investors in shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) was announced concerning whether certain officers and directors of Anthera Pharmaceuticals Inc breached their fiduciary duties by paying certain top officials at Anthera Pharmaceuticals excessive compensation.

The investigation by a law firm focuses on whether certain directors and officers of Anthera Pharmaceuticals Inc (harmed the company by agreeing to pay certain of Anthera Pharmaceuticals’ senior officers and executives excessive compensation.

Anthera Pharmaceuticals Inc (NASDAQ:ANTH) reported that its Net Loss increased from $12.20 million in 2009 to $95.33 million in 2011.

Shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) declined from as high as $8.28 per share in February 2012 to as low as $0.60 per share in November 2012.

The total compensation of certain top officials at Anthera Pharmaceuticals Inc increased significantly between 2009 and 2011. For instance, the President and CEO’s total compensation rose from over $369,000 in 2009 to over $1.48 million in 2011, the Chief Business Officer and CFO’s pay increased from over $264,000 in 2009 to over $943,000 in 2011, and the Chief Medical Officer’s total compensation increased from over $289,000 in 2009 to over $936,000 in 2011.

On January 24, 2013, NASDAQ:ANTH closed at $0.713 per share.